Abstract:Circulation Research, Ahead of Print. BACKGROUND:Chronic overconsumption of lipids followed by their excessive accumulation in the heart leads to cardiomyopathy. The cause of lipid-induced cardiomyopathy involves a pivotal role for the proton-pump vacuolar-type H+-ATPase (v-ATPase), which acidifies endosomes, and for lipid-transporter CD36, which is stored in acidified endosomes. During lipid overexposure, an increased influx of lipids into cardiomyocytes is sensed by v-ATPase, which then disassembles, causing endosomal de-acidification and expulsion of stored CD36 from the endosomes toward the sarcolemma. Once at the sarcolemma, CD36 not only increases lipid uptake but also interacts with inflammatory receptor TLR4 (Toll-like receptor 4), together resulting in lipid-induced insulin resistance, inflammation, fibrosis, and cardiac dysfunction. Strategies inducing v-ATPase reassembly, that is, to achieve CD36 reinternalization, may correct these maladaptive alterations. For this, we used NAD+-precursor nicotinamide mononucleotide (NMN), inducing v-ATPase reassembly by stimulating glycolytic enzymes to bind to v-ATPase.METHODS:Rats/mice on cardiomyopathy-inducing high-fat diets were supplemented with NMN and for comparison with a cocktail of lysine/leucine/arginine (mTORC1-mediated v-ATPase reassembly). We used the following methods: RNA sequencing, mRNA/protein expression analysis, immunofluorescence microscopy, (co)immunoprecipitation/proximity ligation assay (v-ATPase assembly), myocellular uptake of [3H]chloroquine (endosomal pH), and [14C]palmitate, targeted lipidomics, and echocardiography. To confirm the involvement of v-ATPase in the beneficial effects of both supplementations, mTORC1/v-ATPase inhibitors (rapamycin/bafilomycin A1) were administered. Additionally, 2 heart-specific v-ATPase-knockout mouse models (subunits V1G1/V0d2) were subjected to these measurements. Mechanisms were confirmed in pharmacologically/genetically manipulated cardiomyocyte models of lipid overload.RESULTS:NMN successfully preserved endosomal acidification during myocardial lipid overload by maintaining v-ATPase activity and subsequently prevented CD36-mediated lipid accumulation, CD36-TLR4 interaction toward inflammation, fibrosis, cardiac dysfunction, and whole-body insulin resistance. Lipidomics revealed C18:1-enriched diacylglycerols as lipid class prominently increased by high-fat diet and subsequently reversed/preserved by lysine/leucine/arginine/NMN treatment. Studies with mTORC1/v-ATPase inhibitors and heart-specific v-ATPase-KO mice further confirmed the pivotal roles of v-ATPase in these beneficial actions.CONCLUSION:NMN preserves heart function during lipid overload by preventing v-ATPase disassembly.

Reversal of Hypertriglyceridemia, Fatty Liver Disease, and Insulin Resistance by a Liver-Targeted Mitochondrial Uncoupler.

Sustained-release Mitochondrial Protonophore Reverses Nonalcoholic Fatty Liver Disease in Rats

Controlled-release Mitochondrial Protonophore Reverses Diabetes and Steatohepatitis in Rats.

Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet

Combined Treatment with Ultrasound-Targeted Microbubble Destruction Technique and NM-aFGF-loaded PEG-nanoliposomes Protects Against Diabetic Cardiomyopathy-Induced Oxidative Stress by Activating the AKT/GSK-3β1/Nrf-2 Pathway

32-OR: Coordination of Mitochondrial Uncoupling with Pyruvate Dehydrogenase Activation Safely Ameliorates Hyperglycemia through Preferential Glucose Oxidation

Mitochondrial Uncoupling Coordinated With Pdh Activation Safely Ameliorates Hyperglycemia Via Promoting Glucose Oxidation

Eliciting the Mitochondrial Unfolded Protein Response by Nicotinamide Adenine Dinucleotide Repletion Reverses Fatty Liver Disease in Mice

Hdmcp Uncouples Yeast Mitochondrial Respiration And Alleviates Steatosis In L02 And Hepg2 Cells By Decreasing Atp And H2o2 Levels: A Novel Mechanism For Nafld

MLN4924 Treatment Diminishes Excessive Lipid Storage in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease (NAFLD) by Stimulating Hepatic Mitochondrial Fatty Acid Oxidation and Lipid Metabolites

Liver-targeted Nano-MitoPBN Normalizes Glucose Metabolism by Improving Mitochondrial Redox Balance

Betaine Alleviates Nonalcoholic Fatty Liver Disease (NAFLD) Via a Manner Involving BHMT/FTO/m6A/ PGC1α Signaling.

Compartmentally scavenging hepatic oxidants through AMPK/SIRT3-PGC1 axis improves mitochondrial biogenesis and glucose catabolism

Treatment With Ppar Delta Agonist Alleviates Non-Alcoholic Fatty Liver Disease By Modulating Glucose And Fatty Acid Metabolic Enzymes In A Rat Model

Synergistic activation of AMPK by AdipoR1/2 agonist and inhibitor of EDPs–EBP interaction recover NAFLD through enhancing mitochondrial function in mice

A novel fatty acid mimetic with pan-PPAR partial agonist activity inhibits diet-induced obesity and metabolic dysfunction-associated steatotic liver disease

224-OR: Antisense Oligonucleotide–Mediated Restriction of Mitochondrial Pyruvate Metabolism Limits DNL in High-Fat Fed C57BL6/J Mice

Glycolysis-Mediated Activation of v-ATPase by Nicotinamide Mononucleotide Ameliorates Lipid-Induced Cardiomyopathy by Repressing the CD36–TLR4 Axis

Dihydromyricetin Ameliorates Nonalcoholic Fatty Liver Disease by Improving Mitochondrial Respiratory Capacity and Redox Homeostasis Through Modulation of SIRT3 Signaling

Reversal of High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease by Metformin Combined with PGG, an Inducer of Glycine N-Methyltransferase

Diabetes reversal by inhibition of the low-molecular-weight tyrosine phosphatase